Related Experiment Video
Updated: Apr 25, 2026
10:10
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
Published on: November 8, 2016
8.1K
Utilizing regulatory T cells against rheumatoid arthritis
Mohammad Haque1, Kristin Fino1, Fengyang Lei1
1Department of Microbiology and Immunology, Pennsylvania State University College of Medicine , Hershey, PA , USA.
Frontiers in Oncology
|August 26, 2014
Summary
Regulatory T (Treg) cells are crucial for immune balance. Foxp3(+) Treg cells show promise for treating rheumatoid arthritis, especially tissue-associated types, offering localized suppression without systemic effects.
Area of Science:
- Immunology
- Cell Biology
- Autoimmunity
Background:
- Regulatory T (Treg) cells are vital for immune surveillance and preventing autoimmune diseases.
- Foxp3(+) Treg cells maintain self-tolerance by suppressing excessive immune responses.
- The roles of Foxp3(-) Treg cells in immunity and autoimmunity are not fully understood.
Purpose of the Study:
- To discuss the phenotypes and functions of Foxp3(+) Treg cells.
- To explore the therapeutic potential of Foxp3(+) Treg cells in rheumatoid arthritis (RA).
Main Methods:
- Review of existing literature on Treg cell phenotypes and functions.
- Analysis of the suppressive capabilities of various Treg cell populations.
- Discussion of potential therapeutic strategies using Treg cells for RA.
Main Results:
- Foxp3(+) Treg cells are critical for immune homeostasis and preventing autoimmunity.
- Tissue-associated or antigen-specific Treg cells demonstrate superior efficacy in suppressing local autoimmune conditions like RA.
- Expanding Foxp3(+) Treg cells from stem cells may enhance stability and prevent systemic immunosuppression.
Conclusions:
- Foxp3(+) Treg cells hold significant therapeutic potential for autoimmune diseases, particularly RA.
- Targeting tissue-associated Treg cells offers a promising strategy for localized autoimmune disease treatment.
- Stem cell-derived Treg cells may provide a safer and more effective approach to immunotherapy.
Related Concept Videos
01:24T Cell Types and Functions
3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
01:28Inflammatory Response
12.4K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
12.4K
01:20The JAK-STAT Signaling Pathway
10.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.1K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
867
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
867
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
744
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
744